Validación del índice compuesto DAPSA (Disease Activity for Psoriatic Arthritis) en una cohorte de pacientes con artritis psoriásica en Argentina y determinación de sus valores de corte

J. Gallino Yanzi; E.E. Schneeberger; O. Cerda; C.A. Zaffarana; M. Landi; M. Rosemffet; N. Zamora; T. Cazenave; F. Dal Pra; M.P. Kohan; E. Buschiazzo; G. Citera

doi:10.47196/rar.v27i3.583

J. Gallino Yanzi Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Argentina
E.E. Schneeberger Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Argentina
O. Cerda Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Argentina
C.A. Zaffarana Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Argentina
M. Landi Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Argentina
M. Rosemffet Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Argentina
N. Zamora Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Argentina
T. Cazenave Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Argentina
F. Dal Pra Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Argentina
M.P. Kohan Hospital General de Agudos Dr. E. Tornú, Ciudad Autónoma de Buenos Aires, Argentina
E. Buschiazzo Hospital Señor del Milagro, Salta, Argentina
G. Citera Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Argentina

DOI: https://doi.org/10.47196/rar.v27i3.583

Palabras clave: artritis psoriásica, DAPSA, índice de actividad

Resumen

Objetivos: Validar el índice DAPSA en pacientes con Artritis Psoriásica (APs) en Argentina, comparar su rendimiento con índices compuestos y con la ultrasonografía (US) y establecer valores de corte.

Citas

I. Arturi A. Diagnóstico en Reumatología y Enfermedades Autoinmunes Sistémicas. Edición Abbvie. Capítulo 8. Pág. 197-202.2014.

II. Maldonado Cocco J, Citera G. Reumatología. Segunda Edición, Ediciones Azzurras. Capítulo 33. Pág 462-70. 2012.

III. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993;36(6):729-40.

IV. Wong PC, Leung YY, Li EK, Tam LS. Measuring Disease Activity in Psoriatic Arthritis. Int J Rheumatol 2012;2012:839425. doi: 10.1155/2012/839425. Epub 2012 Dec 25.

V. CastrejonI, Ortiz AM, García Vicuña R, López Bote JP, Humbría A, Carmona L, González Álvaro I. Are the C-reactive protein values and erythrocyte sedimentation rate equivalent when estimating the 28-joint disease activity score in rheumatoid arthritis? Clin Exp Rheumatol 2008;26(5):769-75.

VI. Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatolology 2003;42(2):244-57.

VII. Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005;7(4):796-806.

VIII. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21(12):2286-91.

IX. Gladman DD, Inman RD, Cook RJ, Maksymowych WP, Braun J, Davis JC, et al. International spondyloarthritis interobserver reliability exercise— the INSPIRE study: I. Assessment of spinalmeasures, J Rheumatol 2007;34(8):1733-9.

X. Taylor W, Harrison A. Could the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) be a valid measure of disease activity in patients with psoriatic arthritis? Arthritis Rheum 2004;51(3):311-5.

XI. Carrillo I, González M. Landi M, Maldonado Ficco H, Maldonado Cocco J, Giraldo C, et al. Desempeño del BASDAI en artritis psoriática ¿es útil para medir actividad periférica? (abstract) Rev Argent Reumatol 2012;23(Supl5):60.

XII. Mease P.Measures of Psoriatic Arthritis. Arthritis Care Res 201;63(11)64-85.

XIII. Schoels M, Aletaha D, Funovits J, Kavanaugh A, Baker D, Smolen JS. Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis 2010;69(8):1441-7.

XIV. Clegg DO, Reda DJ, Mejias E, Cannon GW, Weisman MH, Taylor T, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996;39 (12):2013-20.

XV. G ladman DD, Tom BD, Mease PJ, Farewell VT. Informing response criteria for psoriatic arthritis (PsA). II: Further considerations and a proposal--the PsA joint activity index. J Rheumatol. 2010;37(12):2559-65.

XVI. Helliwell PS, FitzGerald O, Fransen J, Gladman DD, Kreuger GG, Callis-Duffin K, et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis. 2013;72(6):986-9.

XVII. Mumtaz A, Gallagher P, Kirby B, Waxman R, Coates LC, Veale JD, et al. Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis 2011;70(2):272-7.

XVIII. Husic R, Gretler J, Felber A, Graninger W, Duftner C, Hermann J, et al. Disparity between ultrasound and clinical findings in psoriatic arthritis. Ann Rheum Dis 2014;73(8):1529-36.

XIX. E berl G, Studnicka-Benke A, Hitzelhammer H, Gschnait F, Smolen Jet al. Development of a Disease Activity index for the assessment of REactive Arthritis (DAREA). Rheumatology 2000;39(2):48-55.

XX. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54(8):2665-73.

XXI. W olfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33(2):160-72.

XXII. Doward LC, Spoorenberg A, Cook SA, Whaley D, Helliwell PS, Kay LJ, et al. Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis 2003;62(1):20-6.

XXIII. M cKenna SP, Doward LC, Whalley D, Tennant A, Emery P, Veale DJ. Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis. Ann Rheum Dis 2004;63(2):162-9.

XXIV. Citera G, Arriola MS, Maldonado Cocco JA, Rosemffet MG, Sánchez MM, Goñi MA, et al. Validation and crosscultural adaptation of an Argentine Spanish version of the health assessment questionnaire disability index. J Clin Rheumatol 2004;10(3):110-5.

XXV. C alin A, Garrett SL, Whitelock H, Kennedy LG, O’Hea J, Mallorie P, et al. A new approach to functional ability in ankylosing spondylitis. J Rheumatol 1994;21(12):2281-5.

XXVI. Smolen JS, Schoels M, Aletaha D. Disease activity and response assessment in psoriatic arthritis using the Disease Activity index for PSoriatic Arthritis (DAPSA). Clin Exp Rheumatol 2015;33(Suppl.93):S48-S50.

XXVII. Helliwell P, Kavanaugh A. Comparison of composite measures of disease activity in psoriatic arthritis using data from an interventional study with golimumab. Arthritis Care Res 2014; 66(5):749-56.

XXVIII. Salaffi F, Ciapetti A, Carotti M, Gasparini S, Gutierrez M. Disease activity in psoriatic arthritis: Comparison of the discriminative capacity and construct validity of six composite indices in real world. Biomed Res Int 2014;2014.528105.doi:10.1155/2014/ 528105.

XXIX. Mease P. Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Arthritis Care Res 2011;63(11):S64-85.

XXX. T heander E, Husmark T, Alenius G, Larsson P, Teleman A, Geijer M, et al. Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA). Ann Rheum Dis 2014;73(2): 407-13.

XXXI. Fitzgeral O, Helliwell P, Mease P, Mumtaz A, Coates L, Pedersen R, et al. Application of composite disease activity scores in psoriatic arthritis to the PRESTA data set.Ann Rheum Dis 2012;71(3):358-62.

XXXII. Michelsen B, Diamantopoulos A, Hammer H, Soldal D, Kavanaugh A, Haugeberg G. Ultrasonographic evaluation in psoriatic arthritis is of major importance in evaluating disease activity. Ann Rheum Dis 2016 April 18.pii: annrheumdis-2015-208806.doi 10.1136/ annrheumdis-2015-208806. [Epub ahead of print]

XXXIII. P errotta F, Marchesoni A, Lubrano E. Minimal disease activity and remission in psoriatic arthritis patients treated with anti TNF± drugs. J Rheumatol 2016;43(2):350-5.

XXXIV. S choels M, Aletaha D, Alasti F, Smolen J. Disease Activity in Psoriatic Arthritis: defining remission and treatment success using the DAPSA score. Ann Rheum Dis 2016;75(5):811-8.